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Heart rate (HR) variability and large arterial compliance can be improved using fish oils. DHA, a component of fish oil, has cardiovascular health
benefits, but its effect on HR variability (HRV) and arterial compliance is yet to be quantified. Sixty-seven overweight or obese adults (thirty-six
males and thirty-one females; 53 (SEM 2) year; BMI 31·7 (SEM 1·1) kg/m2) were randomly allocated to consume either 6 g/d sunola oil (control;
n 17), fish oil (260 mg DHA þ 60 mg EPA per g) at doses of 2 g/d (n 16), 4 g/d (n 17) or 6 g/d (n 17). Blood pressure, HR and compliance of large
and small arteries were measured while supine at baseline and after 12 weeks in all participants, and HRV was assessed in a subgroup of forty-six
participants. There was no effect of fish oil on blood pressure, small artery compliance or HR. However, the low frequency:high frequency ratio of
HRV decreased with increasing doses of fish oil (r 20·34, P¼0·02), while large artery compliance increased (r 0·34, P¼0·006). Moreover, the
changes in these biomarkers were significantly correlated (r 20·31, P¼0·04) and may reflect fish oil-induced improvements in arterial function
and cardiac autonomic regulation.
n-3 PUFA: DHA: Cardiovascular health: Cardiac autonomic balance
Elevated heart rate (HR) is a risk factor for cardiovascular
death, particularly sudden death(1), while impaired HR varia-
bility (HRV) is an indicator of mortality risk both in patients
suffering from heart disease(2) and in the general population(3).
Arterial compliance is also an independent risk factor for
CVD(4) and may contribute to cardiovascular risk by contri-
buting to a reduction in HRV as a result of baroreceptors in
the walls of less compliant arteries, being less able to respond
to changes in blood pressure and therefore provide less sensi-
tive regulation of HRV.
HRV refers to the beat-to-beat alterations in HR thought to
reflect changes in autonomic nervous system activity. In
healthy individuals during rest, the electrocardiogram (ECG)
displays periodic variation in R–R intervals. There are two
important frequency components of HRV, high frequency
(HF, 0·15–0·4 Hz) and low frequency (LF, 0·04–0·15 Hz).
The HF component has been shown to reflect efferent para-
sympathetic activity (predominant at rest), whereas the LF
component reflects sympathetic and parasympathetic inter-
actions as well as baroreceptor activity. The LF:HF ratio of
HRV therefore reflects the balance between the sympathetic
and parasympathetic nervous activity known as sympathova-
gal balance. Depressed HRV has been identified as a cardio-
vascular risk factor and increases the mortality risk among
patients with and without heart disease(2,3).
HRV and arterial compliance are known to be attenuated in
people with elevated levels of TAG(5,6). High TAG are also
strongly associated with obesity and have been evaluated as
a significant risk factor for CVD(7,8). Obesity is an indepen-
dent cardiovascular risk factor; however, the mechanism
underlying this association remains unclear. Several causes
for the relationship between obesity and CVD have been
suggested, including that a reduction in HRV or impaired
arterial compliance might be the means for the increased car-
diovascular risk(9 – 14). It remains unclear whether arterial com-
pliance or HRV measures in obese people with elevated blood
TAG are affected by long-chain n-3 (LC n-3) PUFA in a dose-
dependant manner.
Supplementation of the diet with fish oil containing LC n-3
PUFA has previously been shown to reduce TAG and
HR(15,16) and improve HRV(17 – 19). Epidemiological evidence
also suggests that HRV is improved in populations that have
a higher intake of LC n-3 PUFA over a prolonged
period(20). The effects of LC n-3 PUFA on HR and HRV
are likely to be attributable to increased parasympathetic acti-
vation(19). We hypothesise that the latter could result from fish
oil-mediated improvements in arterial compliance, thereby
increasing baroreceptor sensitivity.
While the effects of LC n-3 PUFA on HR and HRV could
reduce the risk of cardiovascular events, it is unclear what
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dose is needed to achieve these benefits. The purpose of the
present study was to investigate the dose–response effects
of LC n-3 PUFA on HR and HRV in order to better under-
stand what dose is required to achieve benefit, and to deter-
mine whether some of the effects of LC n-3 PUFA on HR
and HRV might be mediated by improvements in arterial
compliance.
Materials and methods
A randomised, double-blind, placebo-controlled, parallel
dose–response supplementation trial of 12 weeks duration
was undertaken. The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki,
and all procedures involving human subjects were approved
by the Human Research Ethics Committees of the University
of Adelaide and the University of South Australia (Adelaide,
Australia). Written informed consent was obtained from all
subjects before commencement.
Participants
Seventy-five overweight adults (thirty-eight males and thirty-
seven females; 53 (SEM 2) year; BMI 31·7 (SEM 1·1) kg/m2)
were recruited for the study. Participants taking lipid-lower-
ing, blood-thinning or antihypertensive medication, fish oil
supplements or consuming more than one serving of fish per
week were excluded. Participants were all non-smokers and
were instructed to maintain their habitual exercise levels.
Study design
Participants were block matched into four groups that
were stratified according to fasting serum TAG con-
centration. The groups were then randomised to consume
six 1 g oil capsules/d comprising either 0 (n 17), 2 (n 16),
4 (n 17) or 6 (n 17) £ 1 g capsules of DHA-rich fish oil
(NuMega Ingredients, Altona North, Vic, Australia) with the
balance of the capsules made up of 1 g sunola oil (contents
are specified in Table 1) capsules (NuMega Ingredients).
The 2, 4 and 6 g/d doses of fish oil provided 0·52, 1·04 and
1·56 g DHA/d, respectively. Height and weight, HR, arterial
compliance and blood pressure were measured at baseline and
after 12 weeks after an overnight (10–12 h) fast, and blood
was collected by venepuncture. Forty-nine participants who
were willing to undertake an ECG were measured for HRV.
Assessment of erythrocyte fatty acid profiles
The relative proportions of n-3 PUFA in erythrocytes were
determined as described previously, and these assessments
with blood lipids been have reported elsewhere(21).
Resting heart rate, arterial compliance and blood pressure
Assessments of compliance in large (LAC) and small arteries
were obtained using the HDI/Pulsewave CR-2000 Cardiovas-
cular Profiling System (Hypertension Diagnostic, Inc., Eagan,
MI, USA) following 10 min of rest in the supine position. An
appropriate blood pressure cuff was placed about the subject’s
left upper arm, and a rigid plastic wrist support was placed on
the subject’s right wrist to minimise wrist movement and to
stabilise the radial artery during the measurement. An arterial
pulse wave sensor was placed on the skin directly over the
radial artery at the point of the strongest pulse. The non-inva-
sive acoustic sensor was adjusted to the highest relative signal
strength, and the compliance measures were obtained during
30 s of blood pressure waveform collection. This device
measures the decay in diastolic pressure in the large arteries
and the decay in the reflective waves of the small arteries.
Blood pressure and HR were measurements and also recorded
at the same time. Three consecutive measures were collected
and the average recorded. This non-invasive approach is
repeatable and reliable both during long-term and short-term
observations(22).
Heart rate variability
ECG recordings were taken supine for 20 min and recorded
digitally using a biological amplifier (Bio Amp Model
ML132, ADInstruments, Bella Vista, NSW, Australia) linked
to a data acquisition system (Powerlab Model ML880, ADIn-
struments). ECG data were analysed offline by an assessor
Table 1. Composition of fatty acids in 1000mg fish oil
and placebo (sunola oil) capsules
Fatty acid Fish oil (mg) Placebo (mg)
14 : 0 30 –
14 : 1 2 –
15 : 0 10 –
15 : 1 1 –
16 : 0 204 38
16 : 1trans 5 –
16 : 1n-5 6 –
16 : 1n-7 36 1
16 : 1n-9 3 –
16 : 2n-4 1 –
16 : 3n-3 9 –
17 : 0 12 –
17 : 1 8 1
18 : 0 58 35
18 : 1n-7 21 –
18 : 1n-9 134 837
18 : 2n-6 14 63
18 : 3n-3 6 4
18 : 3n-6 2 –
18 : 4n-3 3 –
20 : 0 7 3
20 : 1n-11 12 3
20 : 1n-9 1 –
20 : 2n-6 3 –
20 : 3n-6 2 –
20 : 4n-3 2 –
20 : 4n-6 18 –
20 : 5n-3 (EPA) 56 –
22 : 0 2 –
22 : 1n-11 4 –
22 : 1n-9 3 –
22 : 4n-6 2 –
22 : 5n-3 10 –
22 : 5n-6 16 –
24 : 0 2 –
24 : 1 4 2
22 : 6n-3 (DHA) 262 –
Minor fatty acids 29 13
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who was blinded to the treatments using the HRV Module
1.01 for Chart 5 (ADInstruments). Frequency domain par-
ameters of HRV were derived using power spectrum analysis
(fast Fourier transforms) with high-frequency power (defined
as 0·15–0·40 Hz) and low-frequency power (defined as
0·04–0·15 Hz) expressed in normalised units adjusting for
changes in total power. Poincare plots were used to determine
the normal distribution of HRV. All ECG were recorded
according to the standards of measurements, physiological
interpretation and clinical use guidelines for the assessment
of HRV(23).
Statistics
Statistical analysis was performed using SPSS for Windows
6.0 (SPSS, Chicago, IL, USA). Baseline characteristics
between the treatment groups were compared using one-
way ANOVA. A logarithmic scale was applied to the
LF:HF data to ensure normal distribution for statistical anal-
ysis. The effects of the oil treatments on the dependent
measures over time were analysed using random effects’
mixed models, with oil treatment (dose of DHA-rich fish
oil or control treatment) and time being the factors in the
analysis, with time being the repeated measurement. For sig-
nificant interactions, Bonferroni post hoc pairwise compari-
sons were performed to identify differences between means.
Relationships between oil doses and changes in the depen-
dent measures by week 12 were determined by linear
regression. Changes were compared against baseline values
to detect any regression to the mean. If the latter was
found to be significant, a general linear model was used to
assess treatment-related effects with baseline as a covariate.
Statistical significance was set at P,0·05. All data are
shown as mean (SEM).
Results
Study population
Seventy-five participants were recruited for the study. A sub-
group of fifty-three participants agreed to undergo HRV
assessment. Eight participants withdrew from the trial due to
time constraints or other factors unrelated to the study. Out
of these, four were in the group who underwent HRV assess-
ment. One of the participants in the HRV assessment suffered
an anxiety attack the day before testing at week 12 and did
not complete this assessment. Additionally, data from two
participants who underwent HRV assessment were excluded
as statistical outliers (LF:HF for HRV was .3 standard
deviations from the mean). Thus, at the end of the 12 week
intervention, there were complete data on sixty-seven partici-
pants for LAC, blood pressure and HR and on forty-six
participants for HRV.
Baseline (week 0) characteristics are shown for all partici-
pants in Table 2 and for the subgroup of participants who
underwent HRV assessments in Table 3. No difference in
any parameter was noted between treatment groups at baseline
and there was no significant effect of sex. Baseline and week
12 measurements of LC n-3 PUFA content in erythrocytes
have already been published elsewhere(21). T
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Arterial compliance and blood pressure
There was a significant time £ dose (P¼0·027) effect for
LAC, and post hoc tests revealed that, compared with placebo,
the 6 g dose elicited a significant (P,0·001) improvement
from weeks 0 to 12. Changes in LAC were correlated with
dose of fish oil (r 0·34, P¼0·006) but there was no relationship
with small artery compliance. Changes in LAC were also
correlated with changes in erythrocyte DHA content
(P¼0·02, r 0·29), but not with changes in erythrocyte EPA
(P¼0·077, r 0·22). Although there were no significant differ-
ences between the groups at baseline, regression analysis
showed that the change in LAC correlated with baseline
LAC (r 20·41, P,0·001), raising the possibility that the
result may have been influenced by regression to the mean.
However, analysis by a general linear model comparing treat-
ment groups with placebo showed the following levels of
significance for effects of treatment: 2 g/d, P¼0·408; 4 g/d,
P¼0·784; 6 g/d, P¼0·004. Hence, there was a highly signifi-
cant treatment effect at the highest dose, as well as a
significant correlation with dose, as noted above.
Heart rate
There was no significant effect in time (P¼0·74) or dose
(P¼0·70) with HR. There was no correlation between
change in HR and change in erythrocyte DHA (P¼0·34,
r 20·12) or EPA (r 20·022, P¼0·86) content. However,
changes in HR over 12 weeks correlated significantly with
the corresponding changes in LAC (r 20·48, P,0·001).
Heart rate variability
The individual LF and HF components of HRV showed no
dose £ time effect or correlation with changes in erythrocyte
DHA or EPA content or fish oil dose. However, there was a
significant dose £ time (P¼0·022) effect for the LF:HF
ratio; post hoc tests revealed significant differences from
weeks 0 to 12 for the 4 g (P¼0·0049) and 6 g (P¼0·0015)
doses v. placebo. The LF:HF ratio for HRV decreased with
increasing dose of fish oil (r 20·34, P¼0·023). There was
no correlation of change in LF:HF ratio with change in eryth-
rocyte DHA content (r 0·23, P¼0·13), but there was a strong
correlation with change in erythrocyte EPA content (r 0·47,
P,0·001). Changes in the LF:HF ratio were inversely related
to the corresponding changes in both LAC (r 20·31, P¼0·04)
and MAP (r 0·11, P¼0·024).
Discussion
The present study demonstrates that dietary supplementation
with DHA-rich fish oil over a 12-week period can produce
dose-related improvements in both LAC and HRV. Even
though these were secondary outcome measures in a
broader-based study of dose-related cardiovascular benefits
of DHA-rich fish oil(21), retrospective assessments indicate
that there was 90 and 60 % power, respectively, to detect sig-
nificant treatment effects in LAC and LF:HF ratio at P¼0·05.
Moreover, confidence in these outcomes is strengthened by the
accompanying observations of significant dose relationships
(linear regression) and inter-relationships (LAC changesT
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correlate with LF:HF ratio changes). Impaired arterial compli-
ance and HRV are independent risk factors for CVD(1 – 3,24);
hence, the dose-related increases in both of these parameters
suggest that increased intakes of DHA-rich fish oil are likely
to be associated with dose-related reductions in CVD.
Raised HR per se is a risk factor for CVD(16). A recent
study utilising the HR-lowering drug ivabradine has found
that reducing HR below 70 bpm reduced the incidence of
CHD(25). There is strong evidence that regular consumption
of LC n-3 PUFA can also reduce HR. In a meta-analysis of
thirty-two trials, Mozaffarian et al. (16) found that fish oil con-
sumption for greater than 12 weeks reduced HR, particularly
with groups that had a resting HR equal to or above 69 bpm.
However, in the present study, we did not find a significant
reduction in resting HR, perhaps because resting HR in the
present study was below 69 bpm for each group. Nevertheless,
the dose-related changes in LAC were significantly correlated
with changes in HR.
The dose-related increase in LAC may have facilitated the
improvement in HRV by increasing baroreflex sensitivity, a
possibility that is supported by the observed correlations
between changes in LAC and changes in both HR and
LF:HF ratio. The responsiveness of stretch-sensitive afferent
baroreceptors within the arterial wall would be facilitated
by an increase in LAC, resulting in heightened baroreceptor
sensitivity and afferent input leading to improved autonomic
regulation of HRV. We also found that increasing HRV
correlated with a decreasing MAP, again suggesting enhanced
baroreflex activity.
The increase in LAC was related predominantly to DHA
incorporation in erythrocytes, which is consistent with pre-
vious studies(26,27).On the other hand, the reduction in
LF:HF ratio with increasing dose of fish oil, which indicates
an increasing shift toward parasympathetic regulation,
appeared to be mediated predominantly by EPA. EPA has
been associated with a lower incidence of death from CHD
and arrhythmias(28), and it is known that, compared with
DHA, EPA is more readily incorporated into human atrial
tissue(29). In animal models, dietary fish oils have been
shown to confer resistance to atrial fibrillation(30).The incor-
poration of EPA into atrial tissue is thought to be antiarrhyth-
mic by virtue of EPA’s ability to displace arachidonic acid,
which is known to have pro-arrhythmic properties(31,32).
Thus, increased consumption of EPA and DHA may possibly
improve HRV by both local and baroreflex modulation of
sinoatrial function.
In conclusion, the observed relationships between fish oil
dose and changes in LAC and LF:HF ratio suggest that regular
fish oil supplementation can improve the regulation of HR,
HRV and consequently blood pressure by increasing parasym-
pathetic regulation of cardiac autonomic tone in a dose-depen-
dent manner. These combined benefits may be expected to
reduce CVD risk and provide further justification for increased
intakes of fish oil.
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